Background: The goals of asthma management aim to control the symptoms and minimize future risk. There is, however, an option to stop controller medication if the patient has been well-controlled for at least 6-12 months. To assess control, both clinical symptom assessment and lung function should be monitored periodically. In practical clinical practice of pediatric patients, lung function is not available at all health centers.
Introduction
According to the terms of the Global Initiative for Asthma, the long-term goals for asthma management are to achieve good symptom control, and to minimize future risk of exacerbations, fixed airflow limitation, and side-effects of treatment. Symptom control is assessed using the frequency of daytime & night-time asthma symptoms, reliever use, and activity limitation. Poor symptom control is a risk factor for future exacerbations. Lung function, which mainly focuses on FEV 1 and the FEV 1 /FVC ratio, should be assessed as an indicator of future risk. 1 It is well-established that inflammation in asthma involves not only the large airways, but also the small airways; the complete airway tree. [2] [3] Small airway inflammation is recognized as having an important role in controlling asthma. Increasing evidence suggests that small-airway dysfunction is associated with the clinical features of asthma: such as poor control of asthma and higher numbers of exacerbations. 4 In addition, significant bronchodilator reversibility in a patient taking controller treatment also suggests uncontrolled asthma. 1 When asthma is well-controlled, complete cessation of inhaled corticosteroids (ICS) in adults is not advised as the risk of exacerbations is increased. 1, 5 Nevertheless, a physician may consider stopping controller treatment only if there have
Methods
We conducted a prospective, descriptive study in children diagnosed with asthma according to the GINA guideline, and who regularly attended the Pediatric Asthma Clinic at Srinagarind Hospital, Khon Kaen University, between August 2015 and August 2016. At each visit, the patients were assessed for symptoms and those who met the criteria for symptom -controlled were invited to participate in the study. This study was approved by the Ethics Committee for Human Research of Khon Kean University, Thailand (HE581314)
Study populations
The enrolled asthmatic children were: 1) between 6 and 15 years of age and regularly attended the clinic; 2) symptom -controlled for at least 6 months [as per the GINA 2015 clinical assessment]; 3) regularly used low-dose inhaled controllers (Budesonide ≤ 200 µg/day or Fluticasone ≤ 200 µg/day plus LABA) 1 ; and, 4) able to perform spirometry. Each child participant had informed, written parental consent as well as giving their own assent. Children who had had a respiratory infection in the previous 1 month and had a history of using bronchodilator before performing spirometry within 6 hours were excluded. The symptom control score for the last 1-month of symptoms was determined using the childhood asthma control test (C-ACT). 6 Parents and children who met all the eligibility criteria were asked to perform the C-ACT test before performing spirometry.
Symptom-controlled (GINA clinical assessment)
1 was defined as exhibiting none of the following: daytime symptoms more than twice/week; any night waking due to asthma; any reliever needed for symptoms more than twice/week; and, any activity limitation due to asthma in the past 4 weeks. 6 is a seven-item assessment questionnaire, completed by the child and parent/ caregiver, for assessing asthma control in children between 4 and 11 years of age in the preceding four weeks: the total score ranges between 0 and 27. The C-ACT test has been translated into Thai; however, it has not been validated in Thai children.
Childhood asthma control test (C-ACT)

Pulmonary and small airway function
Lung function was measured using a CHEST multifunctional spirometer HI -801. Typical FEV 1 
Results
There were 40 patients who met the eligibility criteria. There were 26 (65%) males and overall the age ranged between 6.7 and 15.0 years (mean, 10.4 ± 2.0). BMI ranged between 12.4 and 27.2 (mean, 18.3 ± 3.8 kg/m 2 ). No child was diagnosed as obese (i.e., BMI ≥ 95 th percentile). Half of the patients had a co-morbidity with the allergic rhinitis. Sixteen (40%) had a family history of smoking by the father and/or grandfather. Other baseline characteristics included mean duration of diagnosed asthma (6.0 ± 3.2 years) and mean duration of taking ICS (5.6 ± 3.3 years). Half of the patients had had a history of admission due to asthma exacerbation prior to being symptom-controlled (average, 2 times). (Table 1 ) No child had severe been no symptoms for 6-12 months and the patient has no risk factors.
1 By comparison, in clinical pediatric practice, routine lung function at each visit is difficult to perform. Moreover, spirometry is not available at all health care centers in our country (Thailand), so assessment of asthma symptom control is accomplished for reviewing the treatment and controller cessation. Even if children have clinical symptom control, the future risk of exacerbations and lung function (especially of the small airways) are unknown. We, thus, conducted the current study to determine lung function with a focus on small airway function as well as the risk of reversibility among children who have been assessed as symptom-controlled. the latter reflecting small airway function. Repeated spirometry was performed 15 minutes after giving inhaled Ventolin Evohaler® plus spacer to determine reversibility of the airway. Abnormal lung function was defined as FEV 1 < 80% predicted, FEV 1 /FVC < 80%, and FEF 25-75 < 65%. Post bronchodilator, the change of FEV 1 > 12% and FEF 25-75 > 30%, was positive for reversibility. [7] [8] Spirometry was performed by the same trained nurse throughout the study. We documented the demographic characteristics, BMI, family history of atopy, co-morbidity, time of asthma diagnosis, and treatment.
Study analysis
Statistical analyses were performed using SPSS version 19. Continuous data were presented as means ± SD, medians, and ranges (minimum to maximum). Categorical data were presented as numbers and percentages of each group. Table 1 . Demographic characteristics of the studied population exacerbation or admission during the past year. The mean C-ACT score was 25.2±1.7. The range of C-ACT for most children was 22 to 27. Only one child had a score as low as 19. Additional diagnoses and treatment are shown in Table 2 .
Lung function outcomes were: mean of predicted FEV 1 84.0 ± 8.1%, FEV 1 /FVC 87.8 ± 6.1%, and FEF 25-75 predicted 85.5 ± 20.0%. Normal large airway function (FEV 1 ≥ 80%) was found in only 72.5% of participants while normal small airway function (FEF 25-75 ≥ 65%) was found in 87.5%. Among the abnormal FEV 1 and FEF , all were of mild severity (FEV 1 > 70%
Disease characteristic
Onset of suspected asthma symptoms (years) mean ± SD median (min -max)
3.5 ± 3. Table 2 . Treatment and symptom control of asthma prior to enrollment predicted) ( Table 4 ). All children who had an abnormal FEV 1 and FEF 25-75 had a C-ACT score between 22 and 27.
The post-bronchodilator results showed airway reversibility as follows: FEV 1 returned to a normal predicted level in 34 patients (85%) while most of the abnormal FEF 25-75 returned to a normal predicted level in 39 patients (97.5%). Among the children with normal lung function, 4 (10%) showed airway reversibility: 2 had both large airway (FEV 1 > 12%) and small airway reversibility (FEF 25-75 > 30%) and another 2 had only small airway reversibility (FEF 25-75 > 30%). (Table 5 ) The clinical characteristic of these 4 children are presented in Table  3 . As for the risk of exacerbation, two had allergic rhinitis as co-morbidities with a history of smoking in the family. Three of them received the maximum dose of ICS at a medium level 
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but none experienced a severe exacerbation or admission in the past year nor were they activity-limited. All of them achieved asthma-control and the ICS could be stepped down to a low dose for more than 6 months, as required before enrollment.
In the abnormal lung function group, none showed any airway reversibility. One child had both mild fixed abnormal FEV 1 
Discussion
This study was conducted to test the hypothesis that all asthmatic children who have achieved symptom controlled with low-dose ICS for at least 6 months have normal lung function of the entire airway but in particular of the small airway. As for asthma management, all of the patients not only have to achieve good symptom control, the future risk of exacerbations should be minimal. One of the important future risks is low FEV 1 . In addition, significant bronchodilator reversibility in a patient taking controller treatment suggests uncontrolled asthma. 1 The current study showed that some children who were supposed to be well-controlled according to their symptom assessment, continued to have both abnormal large and small airway function.
Several studies have been conducted to determine the correlation of symptom assessment and lung function during the treatment follow-up period. Munoz et al. demonstrated that eosinophilic or neutrophilic inflammation persisted in most well-controlled asthma patients despite their condition being controlled. 9 Recent studies, moreover, showed that small airway dysfunction is not only a feature of severe asthma but can also present in patients with mild asthma who have a low level of symptoms and normal FEV 1 values. [10] [11] [12] [13] Huang et al. demonstrated that the majority of children with well-controlled asthma continued to have airway hyper-responsiveness and low small airway function as represented by FEF 25-75 . 14 Many physiological and imaging techniques have been used to evaluate small airway function, including impulse oscillometry, exhaled nitric oxide, inert gas washout, high resolution computed tomography, and spirometry. 15 Spirometry is often readily available and used most frequently in routine clinical practice. Forced expiratory volume in one second (FEV 1 ) and FEV 1 /forced vital capacity (FVC) mainly represent the larger airways, whereas forced expiratory flow between 25% and 75% of forced vital capacity (FEF 25-75 ) reflects small airway function. 15 Rao et al showed that asthmatic children who had a low FEF 25-75 had nearly 3 times the odds (OR 2.8) of systemic corticosteroid use and 6 times the odds of asthma exacerbations (OR 6.3) compared with those who had normal spirometry. In addition, they also concluded that using the percent change in FEF 25-75 may be helpful in identifying bronchodilator responsiveness in asthmatic children with a normal FEV 1 .
8 Due to our limited resources, we used spirometric results (FEF 25-75 predicted) to represent small airway function and pre-post bronchodilator values to determine airway hyper-reactivity. We found that FEF 25-75 did not add more useful information for the detection of abnormal lung function. Nevertheless, among children who had a normal FEV 1 , four (10%) continued to have airway reversibility especially of the small airway. Prior to being considered symptom-controlled, these four children were treated with ICS at a medium dose level. Regarding clinical assessment of future risk of exacerbation, they did not have any striking history, such as a history of severe exacerbation during the preceding year, no activity limitations or C-ACT score between 22-26. Two children had allergic rhinitis as a co-morbidity and environmental smoking exposure. Notwithstanding these clinical characteristics, they were similar to children with normal lung function. The finding of significant bronchodilator reversibility (i.e., an increase in FEV 1 > 12%, FEF 25-75 > 30%) 16 in a patient taking controller treatment suggests persistent uncontrolled asthma, which should be regarded as evidence for further continuing treatment.
1 Early controller cessation in these patients might lead to severe exacerbation and fixed airway obstruction in the future. This study confirmed the usefulness of assessment of small airway reversibility to determine asthma control status in children. 8, 16 The recent international practice guideline for asthma recommends that lung function-especially spirometry-is a useful indicator of exacerbation, so it should be monitored together with clinical assessment at the start of treatment, after 3-6 months of controller treatment, and periodically going forward. [17] [18] Monitoring asthma management in children according to these guidelines is challenging. In general, symptom control assessment as provided by GINA is used routinely for control-based asthma management at most healthcare centers in our country. Nevertheless, several asthma control scores for children-i.e., Chilhood Asthma Control Test (C-ACT)-have been developed to help in clinical assessment. 6 Medication adjustment as well as cessation of controller mainly depended on subjective symptom control assessments. The current study used the GINA assessment at the level of well-controlled as indicating symptom control. 1 We also compared the GINA assessment with the C-ACT score and found that most children who were well-controlled had a C-ACT score in the range of 22 to 27. Only one child whose lung function (both FEV 1 and FEF 25-75 ) was normal had a C-ACT score of 19. The results of our study on symptom-control assessment are similar to the study by Koolen et al. who showed that a C-ACT score correlated well with the GINA criteria and that children who were well-controlled had a C-ACT score in the range of 23 to 27. 19 By comparison, Ito et al. showed that a C-ACT cut-off score of 23 was useful for identifying children with well-controlled asthma (sensitivity 78%; specificity 54%). 20 This C-ACT score has been translated into Thai but is not widely used possibly because it has not yet been validated.
The European Task Force recommends performing spirometry annually as a minimum, when monitoring asthma in children. 18 The results of our study confirmed the usefulness of objective monitoring in asthma patients especially spirometry; however, in our country, spirometry is not available at all levels of health care. The current study demonstrated that even if the clinical assessment (either GINA or C-ACT score) of asthmatic children indicates symptom controlled' , their lung function might not be normal and they may even have airway reversibility. We, therefore, suggest that before considering cessation of controller medication in children over 6 with well-controlled asthma, a lung function test be performed to demonstrate the actual status, if available.
The limitations of this study were that (a) symptom control assessments were done by several pediatricians caring for the patients, so there will be some variation in assessments; (b) no inter-rater variation was performed before enrollment; and (c) we had a small sample size. In addition, it was a cross-sectional study that might not be able to determine the exact future clinical outcomes. Further study with an adequate sample size and long term cohort should be performed to add more evidence to support the clinical practice guideline.
